Biogen Inc. (BIIB)
Biogen Statistics
Share Statistics
Biogen has 146.38M shares outstanding. The number of shares has increased by 0.53% in one year.
| Shares Outstanding | 146.38M |
| Shares Change (YoY) | 0.53% |
| Shares Change (QoQ) | 0.45% |
| Owned by Institutions (%) | 90.15% |
| Shares Floating | 145.63M |
| Failed to Deliver (FTD) Shares | 1.02K |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 3.45M, so 2.35% of the outstanding shares have been sold short.
| Short Interest | 3.45M |
| Short % of Shares Out | 2.35% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 1.68 |
Valuation Ratios
The PE ratio is 13.65 and the forward PE ratio is 7.7. Biogen's PEG ratio is 0.34.
| PE Ratio | 13.65 |
| Forward PE | 7.7 |
| PS Ratio | 2.3 |
| Forward PS | 1.9 |
| PB Ratio | 1.33 |
| P/FCF Ratio | 8.86 |
| PEG Ratio | 0.34 |
Enterprise Valuation
Biogen has an Enterprise Value (EV) of 26.54B.
| EV / Sales | 2.74 |
| EV / EBITDA | 0 |
| EV / EBIT | 9.23 |
| EV / FCF | 10.55 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.4.
| Current Ratio | 1.35 |
| Quick Ratio | 0.9 |
| Debt / Equity | 0.4 |
| Debt / EBITDA | - |
| Debt / FCF | 2.64 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 9.76% and Return on Invested Capital is 18.46%.
| Return on Equity | 9.76% |
| Return on Assets | 5.82% |
| Return on Invested Capital | 18.46% |
| Revenue Per Employee | $1.27M |
| Profits Per Employee | $214.62K |
| Employee Count | 7,605 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 273.8M |
| Effective Tax Rate | 14.37% |
Stock Price Statistics
The stock price has increased by -43.98% in the last 52 weeks. The beta is 0.06, so Biogen's price volatility has been higher than the market average.
| Beta | 0.06 |
| 52-Week Price Change | -43.98% |
| 50-Day Moving Average | 132.61 |
| 200-Day Moving Average | 166.08 |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 1.74M |
Income Statement
In the last 12 months, Biogen had revenue of 9.68B and earned 1.63B in profits. Earnings per share was 11.2.
| Revenue | 9.68B |
| Gross Profit | 9.68B |
| Operating Income | 5.23B |
| Net Income | 1.63B |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | 11.2 |
Balance Sheet
The company has 2.38B in cash and 6.63B in debt, giving a net cash position of -4.26B.
| Cash & Cash Equivalents | 2.38B |
| Total Debt | 6.63B |
| Net Cash | -4.26B |
| Retained Earnings | 19.26B |
| Total Assets | 28.05B |
| Working Capital | 1.93B |
Cash Flow
In the last 12 months, operating cash flow was 2.88B and capital expenditures -359.8M, giving a free cash flow of 2.52B.
| Operating Cash Flow | 2.88B |
| Capital Expenditures | -359.8M |
| Free Cash Flow | 2.52B |
| FCF Per Share | 17.27 |
Margins
Gross margin is 100%, with operating and profit margins of 54.06% and 16.87%.
| Gross Margin | 100% |
| Operating Margin | 54.06% |
| Pretax Margin | 19.7% |
| Profit Margin | 16.87% |
| EBITDA Margin | n/a |
| EBIT Margin | 54.06% |
| FCF Margin | 26% |
Dividends & Yields
BIIB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 7.33% |
| FCF Yield | 11.29% |
Analyst Forecast
The average price target for BIIB is $205, which is 69.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $205 |
| Price Target Difference | 69.3% |
| Analyst Consensus | Hold |
| Analyst Count | 27 |
Stock Splits
The last stock split was on Jan 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | 1.56 |
| Piotroski F-Score | 6 |